Company news
Syndax Pharmaceuticals, Inc. news in 2021
Syndax Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.
Syndax Announces Orphan Drug Designation Granted to SNDX-5613 by European Commission for the Treatment of Acute Myeloid Leukemia
December 21, 2021
Syndax Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
December 19, 2021
Syndax Announces Proposed Public Offering of Common Stock
December 14, 2021
Syndax Announces Pricing of $75.3 Million Public Offering
December 14, 2021
Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
December 12, 2021
Syndax Pharmaceuticals Announces Updated Positive Data Demonstrating Broad Activity and Tolerability of Axatilimab in Patients with Chronic Graft-Versus-Host Disease
December 10, 2021
Syndax Pharmaceuticals Announces Closing of Global Collaboration and License Agreement for Axatilimab
December 8, 2021
Syndax Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Business Update
November 14, 2021
Syndax to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 15, 2021
November 7, 2021
Syndax Pharmaceuticals to Present Updated Data from SNDX-5613 and Axatilimab Clinical Programs During Oral Sessions at 63rd ASH Annual Meeting
November 3, 2021
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases
September 26, 2021
Syndax Appoints Martin H. Huber, M.D., to its Board of Directors
September 14, 2021
Syndax Announces Participation at Three Upcoming Investor Conferences
September 1, 2021
Syndax Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Business Update
August 8, 2021
Syndax to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 9, 2021
August 1, 2021
SNDX-5613 Granted FDA Fast Track Designation for the Treatment of Relapsed/Refractory Acute Leukemias
June 27, 2021
Syndax Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference
June 2, 2021
Syndax Announces Participation in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 12, 2021
Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update
May 10, 2021
Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
May 3, 2021
Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias
April 19, 2021
Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias
April 14, 2021
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis
April 7, 2021
Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease
March 30, 2021
Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update
March 7, 2021
Syndax to Announce Fourth Quarter and Year-end 2020 Financial Results and Host Conference Call and Webcast on March 8, 2021
February 28, 2021
Calls in 2021
- Syndax Pharmaceuticals (NASDAQ:SNDX) Q3 2021 Earnings Call
Nov 15, 2021
Transcript - Syndax Pharmaceuticals (NASDAQ:SNDX) Q2 2021 Earnings Call
Aug 9, 2021
Transcript - Syndax Pharmaceuticals (NASDAQ:SNDX) Q1 2021 Earnings Call
May 11, 2021
Transcript - Syndax Pharmaceuticals (NASDAQ:SNDX) Q4 2020 Earnings Call
Mar 8, 2021
Transcript
Decks in 2021
- Q3 2021 Earnings Presentation
Earnings · 14 slides · November 2021